Prokidney announces five abstracts selected for presentation at the american society of nephrology's kidney week 2024

Winston-salem, n.c., oct. 14, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced that the company will present five posters, including one late-breaking clinical trial, at the upcoming american society of nephrology's (asn) kidney week being held on october 23-27, 2024, in san diego, ca.
PROK Ratings Summary
PROK Quant Ranking